Background: Telavancin (TLV) is approved in the USA and Europe (methicillin-resistant [MRSA] only) for the treatment of hospital-acquired (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by S. aureus when alternative treatments are not suitable. This study provides a current in vitro activity analysis for TLV and comparators against S. aureus causing HABP in USA hospitals during 2013 – 2014.
Methods: 1,353 S. aureus collected from 29 USA sites located in the nine USA Census regions were included. Susceptibility testing was performed based on CLSI guidelines (M07-A10 and M100-S25). MIC interpretation was guided by FDA (2014), CLSI (2015) and/or EUCAST (2015) criteria. MRSA resistant to ≥3 drug classes were defined as MDR.
Results: TLV had MIC50, MIC90 and MIC100 of 0.03, 0.06 and 0.06 mg/mL, respectively, against methicillin-susceptible, MRSA, non-MDR and MDR subsets. All isolates were inhibited by TLV at the susceptible breakpoint (i.e. ≤0.12 mg/mL). TLV MIC values were at least 16-fold lower than vancomycin (VAN; MIC50/90, 1/1 mg/mL) and linezolid (LZD; MIC50/90, 1/1 mg/mL) MICs against MRSA isolates (all 100.0% susceptible to VAN and LZD). TLV, VAN (MIC50/90, 1/1 mg/mL) and LZD (MIC50/90, 1/1 mg/mL) showed activity against the MDR subset, while other agents had limited coverage. S. aureus with VAN MIC=2 mg/mL had TLV MIC50 (0.06 mg/mL) 2-fold higher than those with VAN MIC at ≤1 mg/mL. However, TLV had MIC100 results of 0.06 mg/mL, regardless of subset.
Conclusion: TLV had potent in vitro activity against S. aureus causing HABP, including less susceptible and MDR subsets, inhibiting all S. aureus at ≤0.06 mg/mL. These results confirm the potent in vitro activity of TLV against S. aureus causing HABP in USA hospitals.
R. E. Mendes,
R. K. Flamm, Theravance Biopharma: Research Contractor , Research support
J. I. Smart, Theravance Biopharma: Employee , Salary
D. J. Farrell, Theravance Biopharma: Research Contractor , Research support
R. N. Jones, Theravance Biopharma: Research Contractor , Research support
See more of: Poster Abstract Session